{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T18:33:55Z","timestamp":1785609235288,"version":"3.56.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T00:00:00Z","timestamp":1678320000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012247","name":"Program of Shanghai Academic Research Leader","doi-asserted-by":"publisher","award":["20XD1424800"],"award-info":[{"award-number":["20XD1424800"]}],"id":[{"id":"10.13039\/501100012247","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81821005"],"award-info":[{"award-number":["81821005"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81903640"],"award-info":[{"award-number":["81903640"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82225046"],"award-info":[{"award-number":["82225046"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.apsb.2023.03.009","type":"journal-article","created":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T11:21:45Z","timestamp":1678533705000},"page":"2601-2612","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Hedgehog pathway orchestrates the interplay of histone modifications and tailors combination epigenetic therapies in breast cancer"],"prefix":"10.1016","volume":"13","author":[{"given":"Xiaomin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyuwei","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanlin","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Shou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6735-1612","authenticated-orcid":false,"given":"Min","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2023.03.009_bib1","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.cell.2018.08.058","article-title":"Targeting epigenetic crosstalk as a therapeutic strategy for EZH2-aberrant solid tumors","volume":"175","author":"Huang","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2023.03.009_bib2","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1126\/science.1118947","article-title":"Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3","volume":"310","author":"Cha","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.apsb.2023.03.009_bib3","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ccr.2010.12.020","article-title":"JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation","volume":"19","author":"Liu","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.apsb.2023.03.009_bib4","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1158\/1541-7786.MCR-17-0034","article-title":"Inhibition of ciliogenesis promotes hedgehog signaling, tumorigenesis, and metastasis in breast cancer","volume":"15","author":"Hassounah","year":"2017","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.apsb.2023.03.009_bib5","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1002\/cam4.833","article-title":"The hedgehog pathway in triple-negative breast cancer","volume":"5","author":"Habib","year":"2016","journal-title":"Cancer Med"},{"key":"10.1016\/j.apsb.2023.03.009_bib6","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/bcr3401","article-title":"The Hedgehog signalling pathway in breast development, carcinogenesis and cancer therapy","volume":"15","author":"Hui","year":"2013","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.apsb.2023.03.009_bib7","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1158\/0008-5472.CAN-10-3738","article-title":"Hedgehog overexpression is associated with stromal interactions and predicts for poor outcome in breast cancer","volume":"71","author":"O'Toole","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2023.03.009_bib8","doi-asserted-by":"crossref","first-page":"5425","DOI":"10.1038\/ncomms6425","article-title":"An epigenetic switch induced by Shh signalling regulates gene activation during development and medulloblastoma growth","volume":"5","author":"Shi","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2023.03.009_bib9","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ccell.2016.08.001","article-title":"Feedback activation of leukemia inhibitory factor receptor limits response to histone deacetylase inhibitors in breast cancer","volume":"30","author":"Zeng","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.apsb.2023.03.009_bib10","doi-asserted-by":"crossref","first-page":"D955","DOI":"10.1093\/nar\/gks1111","article-title":"Genomics of drug sensitivity in cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells","volume":"41","author":"Yang","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.apsb.2023.03.009_bib11","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nature11003","article-title":"The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity","volume":"483","author":"Barretina","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2023.03.009_bib12","doi-asserted-by":"crossref","first-page":"7138","DOI":"10.1158\/1078-0432.CCR-08-0122","article-title":"A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California cancer consortium study","volume":"14","author":"Luu","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2023.03.009_bib13","doi-asserted-by":"crossref","first-page":"3915","DOI":"10.1242\/dev.126.17.3915","article-title":"Regulation of Gli2 and Gli3 activities by an amino-terminal repression domain: implication of Gli2 and Gli3 as primary mediators of Shh signaling","volume":"126","author":"Sasaki","year":"1999","journal-title":"Development"},{"key":"10.1016\/j.apsb.2023.03.009_bib14","doi-asserted-by":"crossref","first-page":"873","DOI":"10.2174\/156652409789105570","article-title":"Hedgehog target genes: mechanisms of carcinogenesis induced by aberrant hedgehog signaling activation","volume":"9","author":"Katoh","year":"2009","journal-title":"Curr Mol Med"},{"key":"10.1016\/j.apsb.2023.03.009_bib15","doi-asserted-by":"crossref","first-page":"6889","DOI":"10.1074\/jbc.C000773200","article-title":"Physical and functional interactions between Zic and Gli proteins","volume":"276","author":"Koyabu","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2023.03.009_bib16","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1074\/jbc.M004430200","article-title":"Molecular properties of Zic proteins as transcriptional regulators and their relationship to GLI proteins","volume":"276","author":"Mizugishi","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2023.03.009_bib17","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ydbio.2013.09.006","article-title":"Pax3 synergizes with Gli2 and Zic1 in transactivating the Myf5 epaxial somite enhancer","volume":"383","author":"Himeda","year":"2013","journal-title":"Dev Biol"},{"key":"10.1016\/j.apsb.2023.03.009_bib18","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1093\/nar\/gkz1120","article-title":"Different class IIa HDACs repressive complexes regulate specific epigenetic responses related to cell survival in leiomyosarcoma cells","volume":"48","author":"Di Giorgio","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.apsb.2023.03.009_bib19","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1182\/blood-2012-08-449140","article-title":"MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor","volume":"121","author":"Chakraborty","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2023.03.009_bib20","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.bcp.2019.07.016","article-title":"The mTOR inhibitor everolimus overcomes CXCR4-mediated resistance to histone deacetylase inhibitor panobinostat through inhibition of p21 and mitotic regulators","volume":"168","author":"Beider","year":"2019","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.apsb.2023.03.009_bib21","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.apsb.2023.03.009_bib22","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/nchembio.1084","article-title":"A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells","volume":"8","author":"Knutson","year":"2012","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.apsb.2023.03.009_bib23","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1038\/ng.3095","article-title":"PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors","volume":"46","author":"Lee","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.apsb.2023.03.009_bib24","doi-asserted-by":"crossref","first-page":"4958","DOI":"10.1093\/nar\/gkq244","article-title":"Characterization of an antagonistic switch between histone H3 lysine 27 methylation and acetylation in the transcriptional regulation of polycomb group target genes","volume":"38","author":"Pasini","year":"2010","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.apsb.2023.03.009_bib25","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/ng.3116","article-title":"Somatic mutations of SUZ12 in malignant peripheral nerve sheath tumors","volume":"46","author":"Zhang","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.apsb.2023.03.009_bib26","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1038\/nbt1010-1045","article-title":"The NIH roadmap epigenomics mapping consortium","volume":"28","author":"Bernstein","year":"2010","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.apsb.2023.03.009_bib27","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1093\/nar\/30.2.475","article-title":"Functional and physical interaction between the histone methyl transferase Suv39H1 and histone deacetylases","volume":"30","author":"Vaute","year":"2002","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.apsb.2023.03.009_bib28","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1126\/science.1149042","article-title":"Demethylation of H3K27 regulates polycomb recruitment and H2A ubiquitination","volume":"318","author":"Lee","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.apsb.2023.03.009_bib29","doi-asserted-by":"crossref","first-page":"a019505","DOI":"10.1101\/cshperspect.a019505","article-title":"Epigenetic determinants of cancer","volume":"8","author":"Baylin","year":"2016","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.apsb.2023.03.009_bib30","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ctrv.2019.04.005","article-title":"Hedgehog signaling inhibitors in solid and hematological cancers","volume":"76","author":"Cortes","year":"2019","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.apsb.2023.03.009_bib31","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jaad.2016.02.1226","article-title":"The 12-month analysis from basal cell carcinoma outcomes with LDE225 treatment (BOLT): a phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma","volume":"75","author":"Dummer","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.apsb.2023.03.009_bib32","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.ccell.2018.11.005","article-title":"Resistance to epigenetic-targeted therapy engenders tumor cell vulnerabilities associated with enhancer remodeling","volume":"34","author":"Iniguez","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.apsb.2023.03.009_bib33","first-page":"1991","article-title":"Combined inhibition of sonic Hedgehog signaling and histone deacetylase is an effective treatment for liver cancer","volume":"41","author":"Li","year":"2019","journal-title":"Oncol Rep"},{"key":"10.1016\/j.apsb.2023.03.009_bib34","doi-asserted-by":"crossref","first-page":"12758","DOI":"10.1073\/pnas.1018510108","article-title":"Dual role of Brg chromatin remodeling factor in Sonic hedgehog signaling during neural development","volume":"108","author":"Zhan","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2023.03.009_bib35","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/ncb2013","article-title":"Histone deacetylase and Cullin3-REN(KCTD11) ubiquitin ligase interplay regulates Hedgehog signalling through Gli acetylation","volume":"12","author":"Canettieri","year":"2010","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.apsb.2023.03.009_bib36","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1002\/ijc.31117","article-title":"Targeting class I histone deacetylases by the novel small molecule inhibitor 4SC-202 blocks oncogenic hedgehog-GLI signaling and overcomes smoothened inhibitor resistance","volume":"142","author":"Gruber","year":"2018","journal-title":"Int J Cancer"},{"key":"10.1016\/j.apsb.2023.03.009_bib37","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1111\/cas.12957","article-title":"Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells","volume":"107","author":"Takashina","year":"2016","journal-title":"Cancer Sci"},{"key":"10.1016\/j.apsb.2023.03.009_bib38","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1349-7006.2009.01387.x","article-title":"Histone deacetylase inhibitor (SAHA) and repression of EZH2 synergistically inhibit proliferation of gallbladder carcinoma","volume":"101","author":"Yamaguchi","year":"2010","journal-title":"Cancer Sci"},{"key":"10.1016\/j.apsb.2023.03.009_bib39","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1182\/blood-2009-03-213496","article-title":"Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells","volume":"114","author":"Fiskus","year":"2009","journal-title":"Blood"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383523000989?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383523000989?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T17:04:22Z","timestamp":1761930262000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383523000989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S2211383523000989"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2023.03.009","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hedgehog pathway orchestrates the interplay of histone modifications and tailors combination epigenetic therapies in breast cancer","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2023.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}